Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression

Date

09 Oct 2016

Session

Breast cancer, metastatic

Presenters

Jeffrey Ross

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

J.S. Ross1, L.M. Gay2, J.A. Elvin2, J. Suh2, J. Vergilio2, S. Ramkissoon2, S. Ali3, V.A. Miller4, P.J. Stephens5

Author affiliations

  • 1 Pathology, Albany Medical Center, 12208 - Albany/US
  • 2 Pathology, Foundation Medicine, Inc., 02141 - Cambridge/US
  • 3 Clinical Development, Foundation Medicine, Inc., 02141 - Cambridge/US
  • 4 Clinical Development, Foundation Medicine, Inc., Cambridge/US
  • 5 Clinical Genomics, Foundation Medicine, Inc., 02141 - Cambridge/US
More

Resources

Background

Breast carcinomas (BC) are commonly classified into 4 subtypes based on hormone receptor expression: basal, luminal A, luminal B, and HER2 overexpressed. Comprehensive genomic profiling (CGP) can reveal targetable genomic alterations (GA) and redefine BC classification into therapeutically relevant subtypes.

Methods

DNA was extracted from 40 µm of FFPE sections for 8654 consecutive BCs. CGP was performed on hybridization-captured, adaptor ligation-based libraries (mean coverage >500X) for up to 315 cancer-related genes. Total mutational burden (TMB) was determined on 1.2 Mbp of sequenced DNA. Clinically relevant GA (CRGA) are GA linked to drugs on the market or under evaluation in clinical trials. Immunotherapy (IO) sensitivity is defined as TMB >20 mut/Mbp or mutation of specific DNA repair pathways. Homologous recombination (HR) deficiency is defined as mutation of the BRCA genes, other genes in the FANC complex, or DNA repair genes that have been shown to confer sensitivity to PARP inhibitors.

Results

Several distinct pathways are altered in BC, and these pathways are targetable with therapies that are FDA approved for oncology indications. Rare mutations can also be found in targetable kinases such as RET, ROS1, and RAF. 6959 (80.4%) tumors harbor a GA in at least one pathway, and 2697 (31.2%) BC harbor alterations in just one pathway (unique cases). Only 9.8% of BC would be HER2-positive by IHC. Table: 229PD

ERBB pathway Hormone therapy resistant (ESR1 mut) HR deficient IO sensitive PI3K/AKT/mTOR pathway FGFR pathway CDK pathway Other kinases
Total Cases 1294 796 1266 419 4375 2650 2685 424
% Total Cases 15% 9% 15% 5% 51% 31% 31% 5%
Unique Cases 274 109 309 48 1442 226 231 58
% Unique Cases 3% 1% 4% 1% 17% 3% 3% 1%
Therapies Trastuzumab, Pertuzumab, Afatinib, Lapatinib, Neratinib Fulvestrant, Tamoxifen Olaparib Pembrolizumab, Nivolumab, Atezolizumab, Ipilumumab Everolimus, Temsirolimus Pazopanib, Ponatinb Palbociclib Sorafenib, Regorafenib, Dabrafenib, Vemurafenib, Crizotinib, Cabozantinib, Sunitinib

Conclusions

CGP can identify CRGA that can stratify tumors by predicted sensitivity to a variety of therapies, including HER2- or mTOR-targeted therapies, immunotherapies, and other kinase inhibitors. 80% of BC harbor targetable GA, and 30% of samples harbor mutations in only one pathway. Many GA would not be identified by IHC or hotspot testing, but can be detected by next-generation sequencing. CGP is a powerful tool for guiding treatment across therapeutically distinct, but targetable, pathways.

Clinical trial identification

Legal entity responsible for the study

Foundation Medicine, Inc.

Funding

Foundation Medicine, Inc.

Disclosure

J.S. Ross: Foundation Medicine, Inc. (compensated), Research Support: Foundation Medicine, Inc. (un-compensated), Stock Ownership: Foundation Medicine, Inc. (compensated). L.M. Gay, J.A. Elvin, J. Suh, J-A. Vergilio, S. Ramkissoon, S. Ali: Employee of and stockholder in Foundation Medicine, Inc. V.A. Miller, P.J. Stephens: Employee of, stockholder in, and holds a leadership position for Foundation Medicine, Inc.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings